NeoGenomics has acquired liquid-biopsy company Inivata for $390m to expand its growing cancer testing capabilities, the companies announced on 5 May.
NeoGenomics exercised a fixed purchase price option, granted in May 2020, to acquire Inivata and expects to close the deal by June 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?